Trial Profile
Evaluate Immunogenicity, Safety and Reactogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-Dose Primary Immunization in Children Before 6 mo of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine
- Indications Otitis media; Pneumococcal infections; Pneumonia
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 12 Aug 2010 Additional location identified [Czech Republic] as reported by ClinicalTrials.gov.
- 09 Jul 2008 Actual patient number (600) added as reported by ClinicalTrials.gov.
- 09 Jul 2008 GlaxoSmithKline Biologicals reported as trial affiliate by ClinicalTrials.gov.